Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MedImmune FluMist Capacity Could Reach 20 Mil. Doses For 2004 Season

  • News

Executive Summary

MedImmune expects up to a five-fold increase in FluMist vaccine supply for the 2004 influenza season

You may also be interested in...



FluMist Reimbursement Is Ahead Of Plan; TV Ads Will Begin Sept. 29

The initial coverage decisions for the FluMist nasal flu vaccine indicate that MedImmune and Wyeth will be able to maintain the $46 per dose price of the vaccine

FluMist Reimbursement Is Ahead Of Plan; TV Ads Will Begin Sept. 29

The initial coverage decisions for the FluMist nasal flu vaccine indicate that MedImmune and Wyeth will be able to maintain the $46 per dose price of the vaccine

FluMist Arriving Ahead Of Schedule; Could Aid Sales, MedImmune Says

MedImmune has begun shipping the first 500,000 doses of the nasal flu vaccine FluMist

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS041741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By